Allon Therapeutics : AL-108 human efficacy data presented to two ICAD 2008 scientific workshops

July 30, 2008 - Clinical trial data presented to two scientific workshops at the International Conference on Alzheimer’s Disease and Related Disorders (ICAD 2008) validate the therapeutic potential of addressing the “tangles” component of the classic Alzheimer’s “plaques and tangles” pathology.

The data from a clinical trial evaluating drug candidate AL-108 in 144 patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease, demonstrated that specific memory function improved in patients who were given AL-108 over 12 weeks...

...AL-108 is being developed by Allon Therapeutics (TSX: NPC), a Canadian biotechnology company located in Vancouver. The drug was discovered by Prof. Gozes of the Sackler Faculty of Medicine at Tel Aviv University. Prof. Collaborative research led by Prof. Gozes has been supported by Tel Aviv University and the U.S. National Institutes of Health... Allon Therapeutics' Press Release -

Allon at BIO Europe Partnering Meeting

April 8, 2008 — Allon Therapeutics Inc. (TSX: NPC), presented at the BIO-Europe Spring 2008 partnership conference in Madrid, Spain sharing with prospective pharmaceutical partners the human efficacy data from the Company’s Phase IIa clinical trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD).

Allon announced February 26, 2008 initial top-line data showing that the Company’s drug AL-108 had a positive impact on memory function in patients with aMCI. Statistically significant, dose dependent and durable improvement was measured in two key cognitive tests, delayed-match-to-sample (DMTS) and digit span, which are widely recognized and validated as effective measures of memory function relevant to Alzheimer’s disease... Allon's Press Release -

Allon Therapeutics, Phase II clinical trial in Alzheimer’s program

December 18, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced that it has completed patient dosing for its Phase II clinical trial evaluating the safety and efficacy of the Company’s proprietary drug candidate AL-108 in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD)...Allon’s program is also the first clinical program to show an effect in animals on both of the classic hallmarks of Alzheimer’s: Neurofibrillary tangles and amyloid beta plaques... Allon's Press Release -